BTIG Maintained Buy on Aldeyra Therapeutics (ALDX) March 17, 2026

BTIG maintained its Buy rating on Aldeyra Therapeutics, Inc. (ALDX) on March 17, 2026, saying the FDA CRL is “hard to defend” but a path to clarity could emerge within 90 days. The note kept a $9.00 price target and left the recommendation unchanged. This ALDX analyst rating keeps institutional confidence visible despite recent volatility. Investors should weigh the maintained Buy against Aldeyra’s market cap of $111,338,147 and recent insider purchases.

ALDX analyst rating: BTIG Maintains Buy

BTIG on March 17, 2026 maintained a Buy rating on Aldeyra Therapeutics and cited the company’s chance to address a Complete Response Letter within 90 days. The firm kept a $9.00 price target in its note and described the CRL as “hard to defend,” suggesting regulatory clarity could re-rate the stock. StreetInsider carried the BTIG note and the firm framed the view as constructive despite the setback source.

Price target and stock reaction

BTIG’s $9.00 price target implies upside from recent levels and anchors the maintained Buy. StreetInsider data attached a 49.19% change equal to $0.61, reflecting short-term price swings after the regulatory update. For traders, the price target gives a clear reference; for longer term holders, it signals expected recovery if clarity arrives.

What the rating means for investors

A maintained Buy means BTIG sees the company’s fundamentals or binary regulatory path as still favorable relative to risk. Investors should treat the ALDX analyst rating as one input, not a sole decision driver. The note raises the probability of a near-term catalyst but also keeps regulatory risk front and center.

Historical analyst coverage and consensus

Analyst coverage on Aldeyra has been mixed but leans positive. Investing.com reports a consensus of Buy from 6 analysts, with 4 Buy, 1 Neutral, and 0 Sell calls across recent coverage source. That context makes BTIG’s maintained Buy consistent with peer sentiment.

Insider activity and market signals

Recent insider buys add a practical layer to the rating discussion. Company insiders reported purchases of $98,000 and $7,100 in ALDX shares within days of the BTIG note, which can signal management confidence amid uncertainty. These transactions should be weighed with the analyst view by risk-aware investors.

Meyka AI view and next steps for investors

Meyka AI rates ALDX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our platform highlights BTIG’s maintained Buy as alignment with the consensus, while flagging the regulatory binary as the primary short-term risk. For active investors we recommend monitoring FDA communications and insider filings and reviewing the $9.00 price target against new data. See the Aldeyra page on Meyka for live updates Meyka ALDX page.

Final Thoughts

BTIG’s March 17, 2026 decision to maintain a Buy on Aldeyra Therapeutics leaves the ALDX analyst rating in positive territory despite a recent CRL. The firm’s $9.00 price target provides a concrete upside benchmark and aligns with the broader analyst consensus that currently favors Buy. Investors should view this maintained Buy as a signal that at least one major analyst believes regulatory issues can be addressed and that a catalyst could arrive within 90 days.

That said, Aldeyra carries binary regulatory risk that can move shares quickly. Combine BTIG’s view with the Meyka AI B+ grade, insider buying signals, and the 6-analyst consensus before sizing positions. These factors give a balanced framework: keep exposure measured, watch for FDA updates, and reassess if new guidance changes the probability of approval or alters the $9.00 target materially. Meyka AI’s real-time tools can help monitor those developments.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.